Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to $57.0 million.

  • Mirum Pharmaceuticals' Shares Outstanding (Diluted Average) rose 1927.73% to $57.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.0 million, marking a year-over-year increase of 1927.73%. This contributed to the annual value of $47.5 million for FY2024, which is 1623.44% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Shares Outstanding (Diluted Average) is $57.0 million, which was up 1927.73% from $49.7 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $57.0 million in Q3 2025 and a low of $30.3 million during Q2 2021
  • For the 5-year period, Mirum Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $40.9 million, with its median value being $40.9 million (2023).
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Shares Outstanding (Diluted Average) skyrocketed by 2455.78% in 2024, and later soared by 417.99% in 2025.
  • Mirum Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $30.4 million in 2021, then rose by 11.9% to $34.0 million in 2022, then rose by 20.31% to $40.9 million in 2023, then rose by 16.23% to $47.5 million in 2024, then increased by 19.93% to $57.0 million in 2025.
  • Its last three reported values are $57.0 million in Q3 2025, $49.7 million for Q2 2025, and $48.9 million during Q1 2025.